Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to ...

Long-term experience using high-dose stereotactic body radiotherapy (SBRT) confirms that this highly focused, rigidly delivered, and tightly controlled radiation approach results in excellent local ...

A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

SAN FRANCISCO ― There was no significant increase in late toxicity when stereotactic body radiation therapy (SBRT) was used in the treatment of early-stage ― but inoperable ― non–small-cell lung ...

Please provide your email address to receive an email when new articles are posted on . Patients with central lung tumors treated with single-fraction radiation did not experience any grade 3 or ...

Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small cell lung cancer Survival outcomes were similar, but ...

Five-year survival rates are among the lowest of all cancers, at about 25%. But when caught early enough – through annual CT ...

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non–Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World ...

A study published this week found that Black Medicare beneficiaries with early-stage NSCLC remain significantly less likely than White beneficiaries to receive curative treatment, largely because of ...

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer The article by Grills ...